Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 20,067 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 20,067 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $28.62, for a total value of $574,317.54. Following the completion of the sale, the president directly owned 822,240 shares of the company’s stock, valued at approximately $23,532,508.80. This represents a 2.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences Price Performance

NYSE RCUS traded down $0.80 on Monday, reaching $28.12. 934,888 shares of the company’s stock traded hands, compared to its average volume of 1,264,033. Arcus Biosciences, Inc. has a 12 month low of $8.84 and a 12 month high of $31.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The stock has a 50-day simple moving average of $25.93 and a 200 day simple moving average of $23.49. The stock has a market cap of $3.54 billion, a PE ratio of -8.84 and a beta of 0.80.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The business had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.48 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The company’s revenue was down 39.3% compared to the same quarter last year. During the same period last year, the business posted ($1.14) earnings per share. As a group, research analysts predict that Arcus Biosciences, Inc. will post -3.66 earnings per share for the current year.

Institutional Investors Weigh In On Arcus Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its position in shares of Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after acquiring an additional 881 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Arcus Biosciences during the fourth quarter worth about $39,000. KBC Group NV purchased a new stake in shares of Arcus Biosciences during the first quarter worth about $50,000. GAMMA Investing LLC grew its stake in shares of Arcus Biosciences by 17.5% in the fourth quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock worth $77,000 after purchasing an additional 482 shares during the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Arcus Biosciences by 14.6% in the first quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock worth $102,000 after purchasing an additional 607 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RCUS. Truist Financial initiated coverage on shares of Arcus Biosciences in a research report on Monday, May 18th. They issued a “buy” rating and a $35.00 target price on the stock. Leerink Partners set a $47.00 price target on shares of Arcus Biosciences in a research report on Monday, April 20th. The Goldman Sachs Group raised their price objective on Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley lifted their price objective on Arcus Biosciences from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Monday, April 20th. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.10.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.